TransCode Therapeutics, Inc. (TransCode), a biopharmaceutical company focused on developing RNA-based therapies for cancer, has announced a public offering of 10,000,000 shares of its common stock at a purchase price of $0.30 per share. The offering is pursuant to a prospectus supplement filed with the SEC under Rule 424(b)(5) and is part of a registration statement previously filed on December 16, 2022. TransCode's common stock is listed on the Nasdaq Capital Market under the symbol 'RNAZ.' On July 22, 2024, the last reported sale price of TransCode's common stock was $0.7925 per share. ThinkEquity LLC has been retained as the exclusive placement agent for the offering and will use reasonable best efforts to arrange for the sale of the securities. The placement agent is...Show More

TransCode Therapeutics, Inc. (TransCode), a biopharmaceutical company focused on developing RNA-based therapies for cancer, has announced a public offering of 10,000,000 shares of its common stock at a purchase price of $0.30 per share. The offering is pursuant to a prospectus supplement filed with the SEC under Rule 424(b)(5) and is part of a registration statement previously filed on December 16, 2022. TransCode's common stock is listed on the Nasdaq Capital Market under the symbol 'RNAZ.' On July 22, 2024, the last reported sale price of TransCode's common stock was $0.7925 per share. ThinkEquity LLC has been retained as the exclusive placement agent for the offering and will use reasonable best efforts to arrange for the sale of the securities. The placement agent is not purchasing or selling any securities and is not required to arrange the purchase or sale of any specific number or dollar amount. The offering does not have a minimum requirement and may sell fewer than all of the securities offered, which could significantly reduce the proceeds received by TransCode. The proceeds from the sale of securities will be available for immediate use by TransCode, despite uncertainty about the effective implementation of its business plan. The offering is expected to close on or about July 24, 2024, subject to customary closing conditions.